Detalhe da pesquisa
1.
A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia.
Mol Cell
; 80(6): 1013-1024.e6, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338401
2.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
3.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood
; 142(12): 1056-1070, 2023 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339579
4.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
5.
Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
Proc Natl Acad Sci U S A
; 118(11)2021 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33836616
6.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Cancer
; 129(12): 1856-1865, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892949
7.
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Blood
; 138(3): 234-245, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292323
8.
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Haematologica
; 108(6): 1500-1514, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226489
9.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Haematologica
; 108(10): 2626-2638, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078252
10.
Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer.
Br J Cancer
; 126(4): 615-627, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34811508
11.
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Haematologica
; 107(1): 58-76, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33353284
12.
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
Haematologica
; 107(6): 1311-1322, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732043
13.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): 1035-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583199
14.
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Cancer
; 127(19): 3541-3551, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34182597
15.
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Cancer
; 127(20): 3761-3771, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34171128
16.
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Cancer
; 127(11): 1894-1900, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33449377
17.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer
; 127(8): 1246-1259, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270904
18.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Br J Haematol
; 195(3): 378-387, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340254
19.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood
; 133(10): 1011-1019, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530801
20.
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Haematologica
; 106(8): 2121-2130, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33853292